ADMA Biologics (NASDAQ: ADMA)
ADMA Biologics (NASDAQ: ADMA)
ADMA Biologics (NASDAQ: ADMA) is a late stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases. ADMA's targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. ADMA's three FDA-licensed approved products including ASCENIV™ (Immune Globulin Intravenous - slra, Human), BIVIGAM® (Immune Globulin Intravenous, Human) are intended to be used by physician specialists focused on caring for immune-compromised patients with infectious diseases.
ADMA also operates ADMA BioCenters, an FDA-licensed, GHA-certified source plasma collection facility which provides a portion of blood plasma for the manufacture of its products.
On October 22, 2013 ADMA Biologics announced the closing of its previously announced initial public offering of 3,352,941 shares of its common stock at a public offering price of $8.50 per share.
ADMA Biologics (NASDAQ: ADMA)
Flexible Stenting Solutions
Flexible Stenting Solutions
Flexible Stenting Solutions (FSS) is a New Jersey based private company developing and commercializing flexible, strong and durable stents that are built on a proprietary FlexStent® technology platform and a unique delivery system. The Company’s broad product platform includes third-generation flexible peripheral arterial, venous, neurovascular and biliary stents. The FSS stents offer advantages over currently available stents including: greater stent flexibility, improved scaffolding and radial strength, and greater fracture and kink resistance. The company’s reconstrainable stent and delivery system offers a unique game changing technology to the peripheral stent market.
Flexible Stenting Solutions was acquired by Cordis Corporation, a division of Johnson & Johnson, on March 12, 2013.
Flexible Stenting Solutions
Glenridge Health
Glenridge Health
Glenridge HealthCare Solutions was founded in a time of massive regulatory reform, managed care upheaval and deep division between payers and providers. Today, more than twenty years later, the industry continues to evolve, and Glenridge has become the leading, national, end-to end provider of total Provider Network Management — building new networks, enhancing existing networks and developing new programs to optimize network performance and provider engagement.
Glenridge team provides comprehensive services that control costs, improve outcomes, ensure compliance and deliver value for national, regional and local clients. The Company has established successful networks for all health plan products including commercial, Medicare Advantage, Medicaid, Duals (MMP), LTSS/HCBS as well as specialty networks including dental, behavioral and workers compensation.
From the outset Glenridge recognized how its technology and project management expertise could improve communication and data analysis, as well as more easily measure effectiveness and prove ROI for our clients. The Company developed proprietary IT systems and methodologies that optimize performance and deliverables. Glenridge has continually expanded its portfolio, and now possesses a set of robust tools that provide tremendous value-added service to our clients. These tools enable the Company to ‘industrialize’ network builds, assure quality and consistency of service, and customize analytics and real-time reporting.
Glenridge Health was acquired by CredSimple on January 13, 2020.
JHL Biotech (TWEM: 6540)
JHL Biotech (TWEM: 6540)
JHL Biotech (TWEM: 6540) was founded in 2012 with a vision of making biopharmaceuticals affordable and accessible to all patients through manufacturing innovation. To achieve this vision, JHL will provide world-class process development and manufacturing services in Asia to companies developing and commercializing high-quality, affordable biologic medicines. JHL is leveraging the latest process and engineering technologies to reduce the complexity and cost of mammalian cell culture manufacturing. These technologies will be incorporated into world-class biologics API manufacturing facilities in Asia that comply with US, EU and ICH cGMP regulations and guidelines.
Led by an experienced team of Genentech and Amgen veterans, and funded by top-tier venture capital firms including Kleiner Perkins Caufield & Byers (KPCB), Sequoia Capital, Biomark Capital and CDIB, JHL is uniquely positioned to deliver manufacturing solutions to its worldwide partners.
On September 17, 2015, JHL Biotech announced its public listing on Taiwan Emerging Stock Board.
Juno Therapeutics (NASDAQ: JUNO)
Juno Therapeutics (NASDAQ: JUNO)
Juno Therapeutics is focused on revolutionizing medicine by re-engaging the body’s immune system to treat cancer. Founded on the vision that the use of human T cells as therapeutics will drive one of the next important phases in medicine, the company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and high-affinity T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno Therapeutics has shown compelling evidence of tumor shrinkage in clinical trials using multiple cell-based product candidates to address refractory B-cell lymphomas and leukemias. Longer term, the company aims to develop its cell-based platform to include additional product candidates to address a broad range of cancers and human diseases.
On December 23, 2014, Juno Therapeutics announced the closing of its initial public offering of 12.7 million shares of common stock at a price to the public of $24.00 per share, which includes the exercise in full by the underwriters of the offering of their option to purchase 1.7 million shares.
On January 22, 2018, Celgene Corporation (NASDAQ:CELG) and Juno Therapeutics (NASDAQ:JUNO) announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Juno.
Lentigen
Lentigen
Lentigen is a diversified biologics company focused on the development and commercialization of breakthrough treatments for human disease. Lentiviral vectors (LV), the company's technology platform, are widely recognized by the scientific community as the most efficient method for delivery of genetic sequence information into cells to reprogram their function. The ability to efficiently and stably reprogram mammalian cells has numerous uses in biotechnology and biomedicine, including drug discovery, target validation, biologics manufacturing and cellular therapies.
Lentigen sold its lentiviral vector manufacturing business and related assets to Miltenyi Biotec, on August 14, 2014.
WaveTec Vision
WaveTec Vision
WaveTec is committed to developing and providing innovative wavefront measurement technology for cataract surgeons. WaveTec's revolutionary ORA System® provides real-time, intraoperative refractive information to ophthalmologists worldwide, allowing them to deliver the best possible vision for their cataract patients.
On August 27, 2014 Alcon, the global leader in eye care and the second largest division of Novartis Group, announced that the company has entered into an agreement to acquire WaveTec Vision.